Novo Nordisk said it would work with ChatGPT maker OpenAI on how to leverage artificial intelligence to discover new drugs, the latest AI partnership in the medical field as healthcare companies seek ...

Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. "Integrating AI in our everyday work gives us the ability to ...

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to support research in biology, drug discovery and translational medicine.

On April 14, Novo Nordisk announced that it had entered into a partnership with OpenAI. The two companies will collaborate to bring cutting-edge artificial intelligence (AI) capabilities to the drug ...

OpenAI published a substantial update to GPT-Rosalind on June 3, 2026, deepening the domain-specialized model's performance across drug discovery, genomics, and wet-lab research — and opening the ...

Novo Nordisk A/S (NYSE:NVO) is included among the 10 Best Affordable Blue Chip Stocks to Buy Now. Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered ...

OpenAI announced Rosalind Biodefense on May 29, 2026, framing it as "defensive acceleration": steering frontier AI toward the institutions that prevent, detect, and respond to biological threats. The ...